MX2021011946A - Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. - Google Patents
Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.Info
- Publication number
- MX2021011946A MX2021011946A MX2021011946A MX2021011946A MX2021011946A MX 2021011946 A MX2021011946 A MX 2021011946A MX 2021011946 A MX2021011946 A MX 2021011946A MX 2021011946 A MX2021011946 A MX 2021011946A MX 2021011946 A MX2021011946 A MX 2021011946A
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- treatment
- methods
- deficency
- disorders associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Marine Sciences & Fisheries (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
De acuerdo con la presente invención, se proporciona una composición farmacéutica que comprende un inhibidor de C1 esterasa, citrato de sodio y que tiene un pH que varía entre 6.5 y 8.0. En una modalidad particular, el inhibidor de C1 esterasa tiene una concentración de 400-600 U/ml. En algunas modalidades, el inhibidor de C1 esterasa comprende la secuencia de aminoácidos de los residuos 23 a 500 de la SEQ ID NO: 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791399P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011946A true MX2021011946A (es) | 2021-11-17 |
Family
ID=51538486
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004724A MX2020004724A (es) | 2013-03-15 | 2014-03-17 | Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. |
| MX2015011281A MX2015011281A (es) | 2013-03-15 | 2014-03-17 | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. |
| MX2021011946A MX2021011946A (es) | 2013-03-15 | 2015-08-28 | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004724A MX2020004724A (es) | 2013-03-15 | 2014-03-17 | Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. |
| MX2015011281A MX2015011281A (es) | 2013-03-15 | 2014-03-17 | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. |
Country Status (30)
| Country | Link |
|---|---|
| US (9) | US9616111B2 (es) |
| EP (3) | EP2968434B1 (es) |
| JP (9) | JP6184581B2 (es) |
| KR (4) | KR20210021146A (es) |
| CN (2) | CN111529708A (es) |
| AU (3) | AU2014232912A1 (es) |
| BR (1) | BR112015023207A8 (es) |
| CA (2) | CA2904543C (es) |
| CY (2) | CY1119419T1 (es) |
| DE (1) | DE202014011208U1 (es) |
| DK (2) | DK3290046T3 (es) |
| EA (1) | EA201591278A1 (es) |
| ES (2) | ES2639833T3 (es) |
| GB (1) | GB2530921B (es) |
| HK (2) | HK1220403A1 (es) |
| HR (2) | HRP20171269T1 (es) |
| HU (2) | HUE036224T2 (es) |
| IL (2) | IL241549B (es) |
| LT (2) | LT3290046T (es) |
| ME (2) | ME03326B (es) |
| MX (3) | MX2020004724A (es) |
| NZ (2) | NZ710730A (es) |
| PL (2) | PL3290046T3 (es) |
| PT (2) | PT2968434T (es) |
| RS (2) | RS58351B1 (es) |
| SG (2) | SG10201707598QA (es) |
| SI (2) | SI2968434T1 (es) |
| TR (1) | TR201900319T4 (es) |
| WO (1) | WO2014145519A2 (es) |
| ZA (3) | ZA201507604B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210021146A (ko) | 2013-03-15 | 2021-02-24 | 샤이어 바이로파마 인코포레이티드 | C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법 |
| EP4162947A1 (en) | 2013-11-22 | 2023-04-12 | Takeda Pharmaceutical Company Limited | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
| KR20170118856A (ko) * | 2015-02-20 | 2017-10-25 | 체에스엘 베링 게엠베하 | C1 에스테라제 억제제의 약제학적 제형 |
| EP3302540A4 (en) * | 2015-05-28 | 2018-08-22 | Cornell University | Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema |
| CA3005906A1 (en) * | 2015-11-19 | 2017-05-26 | Shire Human Genetic Therapies, Inc. | Recombinant human c1 esterase inhibitor and uses thereof |
| EP3493832A1 (en) | 2016-08-05 | 2019-06-12 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
| CA3034568A1 (en) * | 2016-08-23 | 2018-03-01 | Csl Behring Gmbh | Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency |
| US12083171B2 (en) | 2017-05-16 | 2024-09-10 | Octapharma Ag | C1-esterase inhibitor preparation |
| WO2019166572A1 (en) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| JP2021515757A (ja) | 2018-02-28 | 2021-06-24 | ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． | 子癇前症の治療及び予防 |
| AU2019288684A1 (en) | 2018-06-22 | 2021-01-21 | Junten Bio Co., Ltd. | Composition for eliciting infectious immunological tolerance |
| CA3104783A1 (en) | 2018-06-22 | 2019-12-26 | Junten Bio Co., Ltd. | Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte |
| US20210260124A1 (en) | 2018-06-22 | 2021-08-26 | Junten Bio Co., Ltd. | Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte |
| EP4079325A1 (en) * | 2019-12-16 | 2022-10-26 | Nipro Corporation | Aggregation inhibitory agent and medical composition and medical device including same |
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| JP2024525084A (ja) | 2021-07-09 | 2024-07-09 | ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． | Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療 |
| KR20230046146A (ko) | 2021-09-29 | 2023-04-05 | 주식회사 엘지에너지솔루션 | 배터리 제어 시스템 및 방법 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304482A (en) | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
| WO1992022320A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
| DK0716611T3 (da) * | 1993-09-01 | 2002-05-21 | Sanquin Bloedvoorziening | Fremgangsmåde til at reducere myocardielæsion under akut myocardieinfarkt |
| AU1042597A (en) | 1995-12-18 | 1997-07-14 | Stichting Sanquin Bloedvoorziening | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. |
| AT409336B (de) * | 1999-12-22 | 2002-07-25 | Baxter Ag | Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung |
| US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| JP2003521914A (ja) | 2000-01-31 | 2003-07-22 | ファーミング インテレクチュアル プロパティー ベー．フェー． | トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター |
| AU1344102A (en) | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| DE10112617A1 (de) | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren |
| AU2003300781A1 (en) | 2002-09-25 | 2004-05-04 | The Center For Blood Research, Inc. | Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
| WO2004110356A2 (en) | 2003-05-15 | 2004-12-23 | Cbr Institute For Biomedical Research, Inc. | Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity |
| EP1626736B1 (en) | 2003-05-16 | 2020-09-16 | Pharming Intellectual Property B.V. | C1 inhibitor with short half-life for transient treatment |
| US20060233776A1 (en) | 2003-08-19 | 2006-10-19 | Norbert Heimburger | C1-inh as a drug for treating viruses pathogenic to humans |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| CA2654440C (en) | 2005-06-06 | 2013-09-03 | Girish J. Kotwal | Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury |
| JP5219819B2 (ja) | 2005-10-21 | 2013-06-26 | カタリスト・バイオサイエンシーズ・インコーポレイテッド | 補体活性化を阻害する修飾プロテアーゼ |
| SI2380587T1 (en) | 2005-12-21 | 2018-03-30 | Pharming Intellectual Property B.V. | Use of a C1 inhibitor to prevent ischemic reperfusion injury |
| SI1965831T1 (sl) * | 2005-12-21 | 2011-11-30 | Pharming Intellectual Pty Bv | Uporaba C1 inhibitorja za preprečevanje ishemičnih-reperfuzijskih poškodb |
| US7837992B2 (en) | 2006-06-22 | 2010-11-23 | Beth Israel Deaconess Medical Center | C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis |
| CA2678001C (en) | 2007-02-12 | 2017-07-11 | Stefan Schulte | Therapeutic application of kazal-type serine protease inhibitors |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| NZ602498A (en) | 2007-11-30 | 2014-08-29 | Abbvie Inc | Protein formulations and methods of making same |
| US20100143325A1 (en) | 2008-12-09 | 2010-06-10 | Vascular Laboratory, Inc. | Composition And Methods Involving Thrombolytic Agents |
| US9066925B2 (en) | 2009-07-02 | 2015-06-30 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| PL2488203T3 (pl) | 2009-10-16 | 2017-08-31 | Omeros Corporation | Sposoby leczenia rozsianego wykrzepiania wewnątrznaczyniowego przez hamowanie aktywacji dopełniacza zależnej od masp-2 |
| EP3815708A1 (en) | 2010-03-05 | 2021-05-05 | Omeros Corporation | Chimeric inhibitor molecules of complement activation |
| WO2011116291A1 (en) * | 2010-03-18 | 2011-09-22 | Thrombolytic Science International | Production of human c1 inhibitor in human cells |
| WO2013013017A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
| AU2012311483B2 (en) | 2011-09-24 | 2016-03-10 | Csl Behring Gmbh | Combination therapy using immunoglobulin and C1-inhibitor |
| US9452203B2 (en) | 2011-12-22 | 2016-09-27 | Csl Behring Gmbh | Use of C1-inhibitor for the treatment of secondary edema of the central nervous system |
| EP2825205A1 (en) | 2012-03-16 | 2015-01-21 | Belrose Pharma Inc. | Polymeric conjugates of c1-inhibitors |
| WO2014160499A2 (en) | 2013-03-13 | 2014-10-02 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| KR20210021146A (ko) * | 2013-03-15 | 2021-02-24 | 샤이어 바이로파마 인코포레이티드 | C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법 |
-
2014
- 2014-03-17 KR KR1020217004777A patent/KR20210021146A/ko not_active IP Right Cessation
- 2014-03-17 CN CN202010362851.6A patent/CN111529708A/zh active Pending
- 2014-03-17 ES ES14762343.3T patent/ES2639833T3/es active Active
- 2014-03-17 TR TR2019/00319T patent/TR201900319T4/tr unknown
- 2014-03-17 ES ES17177676T patent/ES2713004T3/es active Active
- 2014-03-17 HU HUE14762343A patent/HUE036224T2/hu unknown
- 2014-03-17 EP EP14762343.3A patent/EP2968434B1/en not_active Revoked
- 2014-03-17 KR KR1020217033628A patent/KR102430453B1/ko active IP Right Grant
- 2014-03-17 LT LTEP17177676.8T patent/LT3290046T/lt unknown
- 2014-03-17 DK DK17177676.8T patent/DK3290046T3/en active
- 2014-03-17 ME MEP-2019-45A patent/ME03326B/me unknown
- 2014-03-17 PL PL17177676T patent/PL3290046T3/pl unknown
- 2014-03-17 JP JP2016503371A patent/JP6184581B2/ja active Active
- 2014-03-17 CN CN201480014712.7A patent/CN105517559A/zh active Pending
- 2014-03-17 EA EA201591278A patent/EA201591278A1/ru unknown
- 2014-03-17 CA CA2904543A patent/CA2904543C/en active Active
- 2014-03-17 SG SG10201707598QA patent/SG10201707598QA/en unknown
- 2014-03-17 LT LTEP14762343.3T patent/LT2968434T/lt unknown
- 2014-03-17 WO PCT/US2014/030309 patent/WO2014145519A2/en active Application Filing
- 2014-03-17 RS RS20190198A patent/RS58351B1/sr unknown
- 2014-03-17 CA CA3054718A patent/CA3054718A1/en not_active Abandoned
- 2014-03-17 SI SI201430368T patent/SI2968434T1/sl unknown
- 2014-03-17 SG SG11201507616VA patent/SG11201507616VA/en unknown
- 2014-03-17 AU AU2014232912A patent/AU2014232912A1/en not_active Abandoned
- 2014-03-17 DE DE202014011208.8U patent/DE202014011208U1/de not_active Expired - Lifetime
- 2014-03-17 BR BR112015023207A patent/BR112015023207A8/pt not_active Application Discontinuation
- 2014-03-17 HU HUE17177676A patent/HUE041837T2/hu unknown
- 2014-03-17 PL PL14762343T patent/PL2968434T3/pl unknown
- 2014-03-17 EP EP17177676.8A patent/EP3290046B1/en active Active
- 2014-03-17 KR KR1020227016244A patent/KR102579789B1/ko active IP Right Grant
- 2014-03-17 NZ NZ710730A patent/NZ710730A/en unknown
- 2014-03-17 EP EP18206413.9A patent/EP3508213A1/en active Pending
- 2014-03-17 DK DK14762343.3T patent/DK2968434T3/en active
- 2014-03-17 NZ NZ751555A patent/NZ751555A/en unknown
- 2014-03-17 SI SI201431032T patent/SI3290046T1/sl unknown
- 2014-03-17 GB GB1519921.9A patent/GB2530921B/en active Active
- 2014-03-17 KR KR1020157022897A patent/KR20150135242A/ko active Application Filing
- 2014-03-17 MX MX2020004724A patent/MX2020004724A/es unknown
- 2014-03-17 RS RS20170802A patent/RS56285B1/sr unknown
- 2014-03-17 PT PT147623433T patent/PT2968434T/pt unknown
- 2014-03-17 MX MX2015011281A patent/MX2015011281A/es active IP Right Grant
- 2014-03-17 ME MEP-2017-182A patent/ME02865B/me unknown
- 2014-03-17 PT PT17177676T patent/PT3290046T/pt unknown
-
2015
- 2015-08-28 MX MX2021011946A patent/MX2021011946A/es unknown
- 2015-09-10 IL IL241549A patent/IL241549B/en active IP Right Grant
- 2015-09-15 US US14/855,168 patent/US9616111B2/en active Active
- 2015-10-13 ZA ZA2015/07604A patent/ZA201507604B/en unknown
-
2016
- 2016-07-19 HK HK16108590.9A patent/HK1220403A1/zh unknown
-
2017
- 2017-01-20 US US15/411,744 patent/US20170224788A1/en not_active Abandoned
- 2017-03-16 JP JP2017051361A patent/JP6422520B2/ja active Active
- 2017-08-18 HR HRP20171269TT patent/HRP20171269T1/hr unknown
- 2017-09-12 CY CY20171100961T patent/CY1119419T1/el unknown
- 2017-10-12 ZA ZA2017/06929A patent/ZA201706929B/en unknown
- 2017-12-11 US US15/837,938 patent/US10130690B2/en active Active
- 2017-12-11 US US15/837,969 patent/US10201595B2/en active Active
- 2017-12-11 US US15/837,677 patent/US10080788B2/en active Active
- 2017-12-11 US US15/837,693 patent/US10105423B2/en active Active
-
2018
- 2018-04-06 JP JP2018073691A patent/JP6473536B2/ja active Active
- 2018-04-06 JP JP2018073689A patent/JP6473534B2/ja active Active
- 2018-04-06 JP JP2018073690A patent/JP6473535B2/ja active Active
- 2018-08-02 US US16/053,457 patent/US11534482B2/en active Active
- 2018-08-10 HK HK18110262.0A patent/HK1250912B/zh unknown
- 2018-09-05 US US16/122,015 patent/US20190160158A1/en not_active Abandoned
- 2018-09-17 AU AU2018229558A patent/AU2018229558B2/en active Active
- 2018-10-12 ZA ZA2018/06793A patent/ZA201806793B/en unknown
-
2019
- 2019-01-25 JP JP2019011084A patent/JP6877472B2/ja active Active
- 2019-01-25 JP JP2019011082A patent/JP6877471B2/ja active Active
- 2019-01-25 JP JP2019011079A patent/JP6877470B2/ja active Active
- 2019-02-11 HR HRP20190270TT patent/HRP20190270T1/hr unknown
- 2019-03-15 CY CY20191100308T patent/CY1121653T1/el unknown
- 2019-10-02 US US16/591,184 patent/US11364288B2/en active Active
-
2020
- 2020-05-15 AU AU2020203183A patent/AU2020203183B2/en active Active
- 2020-07-19 IL IL276153A patent/IL276153B/en unknown
-
2021
- 2021-03-02 JP JP2021032716A patent/JP2021088599A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276153B (en) | c1-inh preparations and methods for preventing and treating disorders associated with c1 esterase inhibitor deficiency | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| MX2019010709A (es) | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| PH12017501864A1 (en) | Compositions and methods for treating autism | |
| AU2015311730A8 (en) | CaMKII inhibitors and uses thereof | |
| MX2017013729A (es) | Deteccion especifica de isoformas de clusterina. | |
| MX2018000708A (es) | Composiciones y metodos para desgomar aceite. | |
| EP3294294A4 (en) | Compositions and methods for the treatment or prevention of pulmonary hypertension | |
| IL247616B (en) | Centrally acting acetylcholinesterase inhibitors for the prevention/or treatment of chemically induced neurodegenerative diseases and their symptoms, and corresponding compositions, uses, methods and kit |